Anuh Pharma

Anuh Pharma Current Assets

The Current Assets of Anuh Pharma (ANUHPHR.NS) as of Oct 15, 2026 is 2.13 B INR. In the previous year, Current Assets was 3.86 B INR — a change of -44.85% (lower).

Current Assets

2.13 BINR

YoY

-44.85%

Last updated:

Current Assets of Anuh Pharma is 2026 2.13 B INR. Current Assets of Anuh Pharma was 2025 3.86 B INR. It decreases by -44.85% lower compared to the previous year.

The Anuh Pharma Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
1.52 B INR
Jan 1, 2020
2.23 B INR
Jan 1, 2021
2.38 B INR
Jan 1, 2022
2.62 B INR
Jan 1, 2023
3.11 B INR
Jan 1, 2024
3.41 B INR
Jan 1, 2025
3.86 B INR
Jan 1, 2026
2.13 B INR
The Anuh Pharma Current Assets history
YEARCurrent AssetsYoY
2.13 BINR-44.85%
3.86 BINR+13.19%
3.41 BINR+9.40%
3.11 BINR+18.66%
2.62 BINR+10.40%
2.38 BINR+6.63%
2.23 BINR+46.51%
1.52 BINR-1.29%
1.54 BINR+11.75%
1.38 BINR-1.13%
1.40 BINR-2.79%
1.44 BINR+2,877.25%
48.22 MINR-95.86%
1.17 BINR+41.71%
822.30 MINR-0.17%
823.70 MINR+9.33%
753.40 MINR+49.48%
504.00 MINR-17.09%
607.90 MINR+31.52%
462.20 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Anuh Pharma Stock analysis

What does Anuh Pharma do? Anuh Pharma Ltd is a pharmaceutical company based in Mumbai, India, operating within the healthcare sector. The company, which went public on April 19, 1995, employs 159 full-time staff. It specializes in the manufacturing of active pharmaceutical ingredients (APIs), focusing on various therapeutic categories including Macrolides, Anti-TB, Anti-Bacterials, Anti-Malarial, Anti-Hypertension, Expectorant, and Corticosteroids. The company produces specific products such as Erythromycin variants including Erythromycin Ethyl Succinate, Erythromycin Stearate, Erythromycin Estolate, Erythromycin Propionate, Erythromycin Phosphate, Erythromycin 11,12 Carbonate, and Azithromycin under its Macrolides segment. Anti-TB products include Pyrazinamide and Isoniazid. Anti-Malarial products consist of Sulfadoxine and Pyrimethamine. Anti-Bacterials include Chloramphenicol and Chloramphenicol Palmitate. Anti-Hypertension products feature Losartan Potassium, Telmisartan, and Atorvastatin Calcium. The company also manufactures Ambroxol Hydrochloride as an Expectorant and Moxifloxacin Hydrochloride under Quinolones. Anuh Pharma Ltd maintains a corporate website at https://www.anuhpharma.com/ for further information about its operations and products. Anuh Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Anuh Pharma stock

Current Assets of Anuh Pharma is 2.13 B INR in 2026.

Current Assets of Anuh Pharma changed from 3.86 B INR to 2.13 B INR, representing a -44.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Anuh Pharma since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Anuh Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Anuh Pharma

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Anuh Pharma